Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
LONDON, UK / ACCESSWIRE / May 5, 2022 / Apollon Formularies plc (AQSE:APOL) (“Apollon” or the “Company”), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE:AION) (“Aion”), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that Apollon has acquired certain intellectual property from AI Pharmaceuticals Ltd., a wholly owned Jamaican subsidiary of Aion.
Under the terms of the Agreement, Apollon will acquire the following patents and all associated supporting data including the pre-clinical testing results from BIOENSIS.
Compositions and Methods for Treatment of Cancers.
Compositions and Methods for Treatment of Inflammation.
Methods for Treatment of Human Cancers using Mushroom Compositions.
Methods for Treatment of Human Cancers using Cannabis Compositions.
Apollon has purchased the patents from Aion via a cash payment of £95,957.18 and the issuing of 4,348,679 ordinary shares in the Company. These ordinary shares will be subject to a complete trading restriction for a period of six (6) calendar months from the date of the stock transfer. After the six (6) month restriction period, twenty percent (20%) of such stock received will become eligible for trading, and an additional twenty percent (20%) will be tradable at the end of each following three-month period, with all trading restrictions being fully removed at the end of eighteen (18) months.
Read more: https://www.digitaljournal.com/pr/apollon-acquires-intellectual-property-from-aion#ixzz7SPkaxhbY
Apollon Formularies
@apollon_uk
·
1h
As the company grows and our near-term goals are achieved, our medium-term targets include:
??Accessing lucrative export markets
??Expanding treatment facility
??European market entry for #APOL #medicalcannabis products
??Strategic Partnerships operating in other jurisdictions
https://twitter.com/apollon_uk
Kenny , Does that mean we will get some money back . Let's hope
NEW sales forecasts for the medical cannabis market in Europe predict that €353 million-worth of medical cannabis will be sold on the continent in 2022, rising to €2.3 billion by 2026 – a potential 544% increase over the forecast period.
https://businesscann.com/over-340000-patients-in-europe-set-to-benefit-from-medical-cannabis-access-in-2022/
https://businesscann.com/wp-content/uploads/2022/03/BC-Stocks-Jan-28-5.png
You must have missed this announcement as well:
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange and focused on the treatment of various cancer conditions using its proprietary medical cannabis formulations, is pleased to announce it is advancing an application to join the OTCQB Market ("OTCQB") in the United States. Apollon's Ordinary Shares will continue to trade on the Aquis Stock Exchange under the symbol APOL.
The Company decided to undertake this application for a second trading platform for its shares at the request of several US based investors and believes that cross trading on the OTCQB will provide enhanced investor benefits, including easier access for potential investors in North America, increased trading hours and improved trading liquidity.
Apollon is also pleased to announce that it is exploring other possible up-listing options on local and international exchanges to increase investor access. The Company will maintain its existing AQSE listing, in addition to any additional up-listing it may undertake.
The Company believes that, due to the growth it has seen both in terms of the build out of its facilities and the increase in patient enquiries, moving to a more well-established exchange will provide easier trading access for institutional investors and improve liquidity for all shareholders.
Well....52.72% of the shares are held by the directors and the last placing was at 5.00p, so I don't think it will take very long to move the price up once revenue enhancing news lands.
Daily express - yes it's publicity but an express article carries as much credibility as the graffiti on the wall of a public urinal.
It's data that's needed. Not 3D cell culture data, data from real life people showing that APO products make a real difference to their projected outcomes. APO are on the case but it will be some time yet before we hear. Meantime the 2.8p offer price after several months is dipping to 2.6p from time to time.
I kinda think this Co. may have floated a bit early. The repetition of the same twitter information time after time doesn't inspire confidence.
Article in Express with reference to Apollon Formularies
https://www.express.co.uk/life-style/health/1584045/prostate-cancer-treatment-medicinal-cannabis
https://twitter.com/apollon_uk
https://trimedicanna.co.za/
2nd March RNS
“49/51 between Apollon and Tri-Medi Canna respectively”
https://www.investegate.co.uk/apollon-formularies--apol-/rns/joint-venture-with-tri-medi-canna--south-africa/202203020700082913D/
From February:
“CAPE TOWN, Feb 10 (Reuters) - South African President Cyril Ramaphosa said on Thursday his government wants to expand its nascent domestic cannabis industry as it looks to tap global demand and grow local production and exports.”
https://www.reuters.com/world/africa/safricas-ramaphosa-says-government-formalise-cannabis-industry-2022-02-11/
State of the Nation Address:
“South African products have been exported to other African countries, securing them vital supplies and expanding jobs for young South Africans.
While we help existing industries to grow, we are also nurturing new opportunities for growth and jobs.
Government and the private sector have worked closely together to grow the global business services sector from a small group of companies to one of the world’s leading players.
The global business services sector is on track to create 500 000 new jobs over the next few years.
The hemp and cannabis sector has the potential to create more than 130 000 new jobs.
We are therefore streamlining the regulatory processes so that the hemp and cannabis sector can thrive like it is in other countries such as Lesotho.
Our people in the Eastern Cape, KwaZulu-Natal and elsewhere are ready to farm with this age-old commodity and bring it to market in new and innovative forms."
https://www.gov.za/speeches/president-cyril-ramaphosa-2022-state-nation-address-10-feb-2022-0000
https://www.thepresidency.gov.za/
LOL............
https://twitter.com/apollon_uk/status/1506235021593661449
Jamaican physicians will begin treating patients who have HER2+ breast cancer in Jamaica each company's formulations can be available by physician prescription. Will allow us to corroborate these exciting laboratory results by observing the results of treatment in human patients
the updates are great, as soon as this company starts to declare and show sales of the products then the sp will change greatly or it will get bought out. at this price i'm not sure why one of the bigger cannabis businesses wont just buy out and i think they will. they could buy out at double, tripple or more the current company value and thats nothing in comparison to what the others have.
Apollon Formularies
@apollon_uk
·
1m
?? The medical cannabis sector in #Africa is expected to be worth $7.1 billion by 2023, with South Africa making up 70% of the current market. Apollon's JV with Tri-Medi Canna looks to further establish and develop the medical cannabis industry in the country.
https://twitter.com/apollon_uk
https://www.express.co.uk/life-style/health/1584045/prostate-cancer-treatment-medicinal-cannabis
Dr Stephen Barnhill........
https://www.openaccessgovernment.org/medical-cannabis-cancer-treatments/131741/
Apollon Formularies
@apollon_uk
·
58m
#APOL's goal is to reposition Jamaica's medical cannabis industry, in terms of science, research & development, product manufacturing, affordable patient care, and legal export, while becoming an industry leader in the global pharmaceutical & nutraceutical medical cannabis space
Apollon Formularies
@apollon_uk
·
7m
#Apollon was very pleased to announce its signing of tripartite agreements with local Jamaican farmers which will be mutually beneficial for both parties: creating a constant supply of #cannabis for $APOL & supporting traditional growers whilst also providing new opportunities